Francisco Pacheco, MD
Pulmonary Disease · Tucson, AZNPI 1356438428
Payments from drug & device makers
Across 208 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$720
- Insmed, Inc.$388
- Grifols USA, LLC$309
- Boehringer Ingelheim$295
- Amgen$261
- Actelion Pharmaceuticals US, Inc.$245
- plus $2K from 25 others
What the payments were for
- Grants$251%
- Food & beverage$3,93298%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $720 |
| Insmed, Inc. | 14 | $388 |
| Grifols USA, LLC | 16 | $309 |
| Boehringer Ingelheim | 13 | $295 |
| Amgen | 10 | $261 |
| Actelion Pharmaceuticals US, Inc. | 8 | $245 |
| Electromed, Inc. | 23 | $219 |
| Philips North America LLC | 9 | $179 |
| Regeneron Healthcare Solutions, Inc. | 8 | $177 |
| AstraZeneca | 11 | $154 |
| Genentech USA, Inc. | 8 | $142 |
| Inari Medical, Inc. | 1 | $136 |
| Mylan Specialty L.p. | 6 | $119 |
| Jazz Pharmaceuticals Inc. | 5 | $108 |
| Baxter Healthcare | 4 | $80 |
| Novartis | 4 | $74 |
| Merck | 3 | $60 |
| Harmony Biosciences LLC | 2 | $50 |
| Pulmonx Corporation | 2 | $40 |
| Verona Pharma, Inc. | 1 | $34 |
| Vapotherm Inc | 1 | $33 |
| Johnson & Johnson | 2 | $25 |
| Boston Scientific | 1 | $25 |
| Phadia US Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $19 |
| Viatris Specialty LLC | 1 | $17 |
| Apria Healthcare LLC | 1 | $15 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$136
- CT THROMBECTOMY SYSTEM KIT$136
- UPTRAVI$124
- OPSUMIT$124
- Arikayce$123
How this compares
$4,027 in reported general payments places this provider in the 55th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 61 | $267,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 287 | $258,401 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $146,814 |
| OfevNintedanib Esylate | 11 | $141,125 |
| NucalaMepolizumab | 30 | $115,254 |
| Fasenra PenBenralizumab | 12 | $72,378 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 82 | $50,284 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $46,206 |
| Spiriva RespimatTiotropium Bromide | 50 | $35,499 |
| SymbicortBudesonide/Formoterol Fumarate | 87 | $34,378 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $19,716 |
| Spiriva HandihalerTiotropium Bromide | 23 | $18,362 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,815 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,004 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $720 | $416,638403 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $295 | $226,908143 claims |
| Grifols USA, LLCProlastin C | $309 | $146,81413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $154 | $80,584146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Tucson
- Sachin ChaudharyTucson$1.2M
- Abhinav MittalTucson$570K
- Todd LocherTucson$243K
- Christian BimeTucson$175K
- Ravi ChandranTucson$92K
- Billie BixbyTucson$72K
- Swathy PuthalapattuTucson$64K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.